Discontinued cardiovascular drugs in 2015.

摘要: ABSTRACTIntroduction: About 10,000 compounds will be tested for an individual drug to eventually reach the market. It might helpful recapitulating previous failures and identifying main factors of disappointments.Areas covered: In this review, author(s) detailed 7 cardiovascular discontinued after reaching animal studies or Phase I—III clinical trials during 2015. Meanwhile, reasons these discontinuations were reported. Among drugs, most (6 drugs) attributed lack efficacy. general, due efficacy safety demonstrate need development more predictive models. However, recent related showed that absence toxicity in animals provided little virtually no evidential weight adverse reactions would also absent humans. case, microdosing collaborating closely with biotech companies may better choices improve success ratio.Expert opinion: ...